Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “Divestment”), Helix Immuno-Oncology S.A. (“HIO”), representing …

Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020.

Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO …

Helix Biopharma Corp. Provides Corporate Update

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today provides a corporate update.

Helix BioPharma Corp. Announces Second Quarter 2020 Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2020.

Helix BioPharma Corp. Closes $6.0 Million Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016 units of the Company (“Units”) at a price of $1.0332 per Unit, and the concurrent disposition of 1,708,023 shares of the Company’s …

Helix BioPharma Corp. to Present at Noble Capital Markets 16th Annual Investor Conference

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon – Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida – …

Helix BioPharma Corp. Closes $3.0 Million Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 2,940,000 units of the Company (“Units”) and the disposition of shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), representing an 8.5% …

Helix BioPharma Corp. To Present At The Biotech Showcase In San Francisco

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square.

Helix BioPharma Corps. Announces First Quarter 2020 Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2020 ending October 31, 2019.